iShares Genomics Immunology and Healthcare ETF (IDNA)
| Assets | $123.81M |
| Expense Ratio | 0.47% |
| PE Ratio | 24.60 |
| Shares Out | 5.50M |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 0.98% |
| Ex-Dividend Date | Dec 17, 2024 |
| Payout Ratio | 30.28% |
| 1-Year Return | -0.70% |
| Volume | 35,780 |
| Open | 22.27 |
| Previous Close | 22.38 |
| Day's Range | 22.27 - 22.71 |
| 52-Week Low | 21.53 |
| 52-Week High | 25.80 |
| Beta | 0.94 |
| Holdings | 81 |
| Inception Date | Jun 11, 2019 |
About IDNA
Fund Home PageThe iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is issued by BlackRock.
Top 10 Holdings
48.65% of assets| Name | Symbol | Weight |
|---|---|---|
| Exelixis, Inc. | EXEL | 6.62% |
| Gilead Sciences, Inc. | GILD | 5.99% |
| Incyte Corporation | INCY | 4.90% |
| BioNTech SE | BNTX | 4.88% |
| BeiGene, Ltd. | BEIGF | 4.68% |
| Revolution Medicines, Inc. | RVMD | 4.67% |
| Roche Holding AG | ROG | 4.45% |
| Sarepta Therapeutics, Inc. | SRPT | 4.26% |
| Takeda Pharmaceutical Company Limited | 4502 | 4.13% |
| Sanofi | SAN | 4.08% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 17, 2024 | $0.111 | n/a |
| Jun 11, 2024 | $0.111 | Jun 17, 2024 |
| Dec 20, 2023 | $0.169 | Dec 27, 2023 |
| Jun 7, 2023 | $0.071 | Jun 13, 2023 |
| Jun 9, 2022 | $0.136 | Jun 15, 2022 |
| Dec 13, 2021 | $0.256 | Dec 17, 2021 |
News
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakth...
IDNA: Healthcare Dashboard For February
This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheap...
IDNA: Continues To Underperform, But With Long-Term Potential
I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive growth since its inception in 2019, IDNA has experien...
IDNA: Thematic Biotechnology Index Fund Only Suitable For The Long Run
Genomic revolution and pharmacogenomics have strong growth prospects that may enable the iShares Genomics Immunology and Healthcare ETF biotech portfolio to generate supernormal growth. In order to en...
IDNA: Healthcare Dashboard For November
The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same metr...
BlackRock Zeros in on Themed ETFs
The category represents a rapidly growing portion of the issuer's lineup.
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...
IDNA: Healthcare Dashboard For August
Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued.
IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally
The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but pos...
BlackRock Releases Megatrends Report
What to consider for thematic ETFs in 2022 and beyond.
Equity Market Cap For Technologically Enabled Innovation Likely To Grow Exponentially
Investment strategies geared to the future evaluate complex dynamics that can evolve rapidly. As innovation's market share has grown, investment capacity - as measured by average days to trade - also ...
ETF Battles: ARKG Vs IDNA Vs GNOM
Join us for a triple-header to determine the best genomics biotech ETF!
IDNA: Healthcare Dashboard For September
A dashboard with metrics in healthcare industries.
IDNA And Healthcare Dashboard For July
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month.
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
IDNA enables investors to benefit from advancements and commercialization opportunities of the genomics field. Compared to ARKG, this is more of a pure-play gene ETF and is also less volatile.
Healthcare Dashboard For April And Focus On IDNA
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month.
Best Biotech ETFs for Q2 2021
The best biotech ETFs for Q2 2021 are ARKG, IDNA, and XBI.
iShares Genomics Immunology And Healthcare ETF, Overshadowed But Not Irrelevant
Genomics, immunology, and healthcare ETFs have provided strong returns vs the healthcare sector. RKG has led the way but is not the only option.
3 ETFs For More Moderna Bets
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.